7 Ergebnisse
1. FIELD OF THE INVENTION
The present invention relates to the treatment of conditions associated with neuronal activity. Specifically, the invention is drawn to methods and compositions for administering adenosine to inhibit pain syndromes or epilepsy in a patient.
2. BACKGROUND TO THE
TECHNICAL FIELD
The present invention relates to a new adenosine A.sub.1 receptor agonist, particularly, relates to N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as adenosine A.sub.1 receptor agonist; and its new application as adenosine A.sub.1 receptor agonist in preparation of drug or
FIELD OF THE INVENTION
The invention belongs to the field of pharmaceuticals and therapeutics. The invention relates to N.sup.6-substituted adenosine derivatives and N.sup.6-substituted adenine derivatives, manufacturing methods, pharmaceutical compositions comprising such compounds, and uses of
BACKGROUND AND INTRODUCTION TO THE INVENTION
The present invention is directed to a method of screening candidate compounds for anti-seizure activity, and which is concluded to be predictive of other adenosine releasing agent (ARA) therapeutic effects, such as anti-ischemic properties.
Procedures
BACKGROUND OF THE INVENTION
There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the
FIELD OF THE INVENTION
The present invention is generally related to compounds useful as adenosine receptor ligand and more particularly to compounds showing activity as modulators of the andenosine receptor system.
BACKGROUND OF THE INVENTION
Several compounds related to general formula I have been
BACKGROUND OF THE INVENTION
The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and